103 related articles for article (PubMed ID: 16870548)
21. Impact of catechol-O-methyltransferase (COMT) gene polymorphism on promoter methylation status in gastric mucosa.
Tahara T; Shibata T; Arisawa T; Nakamura M; Yamashita H; Yoshioka D; Okubo M; Maruyama N; Kamano T; Kamiya Y; Fujita H; Nagasaka M; Iwata M; Takahama K; Watanabe M; Hirata I
Anticancer Res; 2009 Jul; 29(7):2857-61. PubMed ID: 19596974
[TBL] [Abstract][Full Text] [Related]
22. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of NPM1 gene mutations in acute myeloid leukemia].
Yan LZ; Chen SN; Liang JY; Feng YF; Cen JN; He J; Chang WR; Zhu ZL; Pan JL; Wu YF; Xue YQ; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):289-93. PubMed ID: 17877154
[TBL] [Abstract][Full Text] [Related]
25. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
26. Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis.
Zhu R; Li BZ; Li H; Ling YQ; Hu XQ; Zhai WR; Zhu HG
Pathol Int; 2007 Jun; 57(6):328-36. PubMed ID: 17539963
[TBL] [Abstract][Full Text] [Related]
27. Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas.
Kiss NB; Geli J; Lundberg F; Avci C; Velazquez-Fernandez D; Hashemi J; Weber G; Höög A; Ekström TJ; Bäckdahl M; Larsson C
Endocr Relat Cancer; 2008 Jun; 15(2):609-21. PubMed ID: 18509008
[TBL] [Abstract][Full Text] [Related]
28. The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML.
Zangenberg M; Grubach L; Aggerholm A; Silkjaer T; Juhl-Christensen C; Nyvold CG; Kjeldsen E; Ommen HB; Hokland P
Eur J Haematol; 2009 Nov; 83(5):439-48. PubMed ID: 19563517
[TBL] [Abstract][Full Text] [Related]
29. Methylation and intratumoural heterogeneity of 14-3-3 sigma in oral cancer.
Bhawal UK; Tsukinoki K; Sasahira T; Sato F; Mori Y; Muto N; Sugiyama M; Kuniyasu H
Oncol Rep; 2007 Oct; 18(4):817-24. PubMed ID: 17786341
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
31. Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53.
Lai JC; Cheng YW; Goan YG; Chang JT; Wu TC; Chen CY; Lee H
DNA Repair (Amst); 2008 Aug; 7(8):1352-63. PubMed ID: 18555750
[TBL] [Abstract][Full Text] [Related]
32. A new player SETs in myeloid malignancy.
Trimarchi T; Ntziachristos P; Aifantis I
Nat Genet; 2013 Aug; 45(8):846-7. PubMed ID: 23892662
[TBL] [Abstract][Full Text] [Related]
33. Somatic SETBP1 mutations in myeloid malignancies.
Makishima H; Yoshida K; Nguyen N; Przychodzen B; Sanada M; Okuno Y; Ng KP; Gudmundsson KO; Vishwakarma BA; Jerez A; Gomez-Segui I; Takahashi M; Shiraishi Y; Nagata Y; Guinta K; Mori H; Sekeres MA; Chiba K; Tanaka H; Muramatsu H; Sakaguchi H; Paquette RL; McDevitt MA; Kojima S; Saunthararajah Y; Miyano S; Shih LY; Du Y; Ogawa S; Maciejewski JP
Nat Genet; 2013 Aug; 45(8):942-6. PubMed ID: 23832012
[TBL] [Abstract][Full Text] [Related]
34. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
Lauchle JO; Braun BS; Loh ML; Shannon K
Pediatr Blood Cancer; 2006 May; 46(5):579-85. PubMed ID: 16261595
[TBL] [Abstract][Full Text] [Related]
35. Myeloid neoplasms with der(1)t(1;19) may constitute a specific entity characterized by a cytogenetic biomarker and gene mutations involved in DNA methylation.
Salgado RN; Menezes J; Calvente M; Suela J; Acquadro F; Martínez-Laperche C; Flores R; Trujillo M; Alvarez S; Cigudosa JC
Leuk Lymphoma; 2014 Nov; 55(11):2652-5. PubMed ID: 24635575
[No Abstract] [Full Text] [Related]
36. [Chronic myeloproliferative conditions and chronic myeloid leukemia (new findings and views)].
Chrobák L
Vnitr Lek; 1987 Oct; 33(10):919-26. PubMed ID: 3318100
[No Abstract] [Full Text] [Related]
37. Cytogenetic techniques for myeloid disorders.
Swansbury J
Methods Mol Biol; 2003; 220():43-57. PubMed ID: 12744205
[No Abstract] [Full Text] [Related]
38. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
[No Abstract] [Full Text] [Related]
39. Unexpected phenotype of a typical NPM1 mutant.
Pianta A; Fabbro D; Damiani D; Tiribelli M; Fanin R; Franzoni A; Romanello M; Tell G; Damante G
Br J Haematol; 2009 Dec; 147(5):760-3. PubMed ID: 19737150
[No Abstract] [Full Text] [Related]
40. [ARMS-PCR method for detecting multiple NPM1 mutations].
Jian ZW; Xu F; Shi C; Wan LG; Zhang ZL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1058-62. PubMed ID: 23998612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
